Giving monoclonal antibodies to healthy volunteers in phase 1 trials: Is it safe?

British Journal of Clinical Pharmacology

Volumn 76, Issue 2, 2013, Pages 164-172

  Tranter, Elizabeth ^a   Peters, Gary ^a   Boyce, Malcolm ^a   Warrington, Steve ^a  

^a Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

Author keywords

First in human; Healthy volunteer; Monoclonal antibody; Phase 1; Review; Safety

Indexed keywords

ABCIXIMAB; ALIROCUMAB; AMG 317; BELIMUMAB; CANAKINUMAB; CD18 ANTIBODY; CDA1 ANTIBODY; CMAB 007; ELSILIMOMAB; ENOKIZUMAB; FELVIZUMAB; GSK 679586; INTERLEUKIN 10 ANTIBODY; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PANOBACUMAB; RAXIBACUMAB; ROVELIZUMAB; SB 249417; TB 402; TCN 032; TEFIBAZUMAB; TGN 1412; TRX1 ANTIBODY; UNCLASSIFIED DRUG; YM 337;

ARTICLE; DAILY LIFE ACTIVITY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

FIRST IN HUMAN; HEALTHY VOLUNTEER; MONOCLONAL ANTIBODY; PHASE 1; REVIEW; SAFETY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMAN EXPERIMENTATION; HUMANS; RISK FACTORS;

EID: 84880650385     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12096     Document Type: Article

References (69)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4: 413-415.
2. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
3. th Nov 2006.
4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563.
5. Itoh K, Kano T, Nagashio C, Mimori A, Kinoshita M, Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 1020-1022.
6. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
7. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9: 325-338.
8. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
9. Williams P, O'Connell D, Dewit O and the ABPI Experimental Medicine Expert Network. First in Human Studies: Points to Consider in Study Placement, Design and Conduct. Association of the British Pharmaceutical Industry, January 2011.
10. GlaxoSmithKline. Clinical Study Register. Available at http://www.gsk-clinicalstudyregister.com (last accessed 31 August 2012).
11. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 2009; 6: e1000144. Epub 2009 Sep 8.
12. The National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research. Ethical Principles and Guidelines for the Protection of Human Subjects of Research, The Belmont Report. 1979. Available at http://www.hhs.gov/ohrp/archive/documents/19790418.pdf (last accessed 17 August 2012).
13. Royal College of Physicians. Research on healthy volunteers. J R Coll Physicians Lond 1986; 20: 243-257.
14. Steering Committee on Bioethics. Draft additional protocol to the Convention on Human Rights and Biomedicine on Biomedical Research. Strasbourg: Council of Europe. 2003.
15. Mason JK, McCall Smith RA, Laurie GT. Law and Medical Ethics, 7th edn. London: Butterworths, 2005.
16. United States Office for Human Research Protections (OHRP). Protection of Human Subjects, 56 Federal Register 28003. 1991. Codified at 45 CFR §46.102(f).
17. Kebabjian R. OAG Aviation & PlanecrashInfo.com accident database, 1992-2011. Available at PlaneCrashInfo.com (last accessed 18 March 2013).
18. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA 2005; 294: 826-832.
19. Office for National Statistics. Mortality Statistics: Deaths Registered in England and Wales (Series DR). 2010. Report released 28 Oct 2011.
20. Health and Safety Executive. Risk education statistics. Available at http://www.hse.gov.uk/education/statistics.htm (last accessed 18 March 2013).
21. Turk EE, Riedel A, Pueschel A. Natural and traumatic sports-related fatalities: a 10-year retrospective study. Br J Sports Med 2008; 42: 604-608.
22. United States Parachute Association. Skydiving safety. Available at http://www.uspa.org/AboutSkydiving/SkydivingSafety/tabid/526/Default.aspx (last accessed 18 March 2013).
23. Soreide K, Ellingsen CL, Knutson V. How dangerous is BASE jumping? An analysis of adverse events in 20850 jumps from the Kjerag Massif, Norway. J Trauma 2007; 62: 1113-1117.
24. Sibille M, Donazzolo Y, Lecoz F, Krupka E. After the London tragedy, is it still possible to consider phase I is safe? Br J Clin Pharmacol 2006; 62: 502-503.
25. Darragh A, Kenny M, Lambe R, Brick I. Sudden death of a volunteer. Lancet 1985; 1: 93-94.
26. Indianapolis Star. Healthy 19 year volunteer suicide. 10 February 2004.
27. Johns Hopkins University Internal Investigative Committee. Report of internal investigation into the death of a volunteer research subject, July 2001. Available at http://www.hopkinsmedicine.org/press/2001/july/report_of_internal_investigation.htm (last accessed 22 August 2012).
28. Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV. Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol 1998; 54: 13-20.
29. Lutfullin A, Kuhlmann J, Wensing G. Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1559 subjects. Int J Clin Pharmacol Ther 2005; 43: 217-226.
30. Kumagai Y, Fukazawa I, Momma T, Iijima H, Takayanagi H, Yakemoto N, Kikuchi Y. A nationwide survey on serious adverse events in healthy volunteer studies in Japan. Clin Pharmacol Ther 2006; 79: P71.
31. Saunders J, Wainwright P. Risk, Helsinki 2000 and the use of placebo in medical research. Clin Med 2003; 3: 435-439.
32. Janofsky J, Starfield B. Assessment of risk in research on children. J Pediatr 1981; 98: 842-846.
33. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA 2004; 291: 476-482.
34. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. 2007. Available at http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf (last accessed 22 August 2012).
35. MacFarlane DJ, Smart RC, Tsui WW, Gerometta M, Eidenberg PR, Scott AM. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99m Tc-DI-DD-3B6/22-80B3 Fab′. Eur J Nucl Med Mol Imaging 2006; 33: 648-656.
36. Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR. Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. Am Heart J 2002; 143: 87-94.
37. Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Esslinger HU, Breddin HK, Harder S. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. Br J Clin Pharmacol 2001; 52: 297-305.
38. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, Vincent M, Banfield C, Colbert A, Hoofring S, Starcevic M, Ma P. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 2011; 28: 2530-2542.
39. Allison DE, Gourlay SG, Koren E, Miller RM, Fox JA. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. BioDrugs 2002; 16: 63-70.
40. Porrini AM, De Luca G, Gambi D, Reder AT. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol 1998; 81: 109-115.
41. Bitzan M, Poole R, Mehran M, Sicard E, Brockus C, Thuning-Roberson C, Riviere M. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 3081-3087.
42. Goldwater R, Keirns J, Blahunka P, First R, Holman J. A phase 1 single ascending dose study of ASKP1240 (anti-CD40 MAb) in healthy subjects [abstract]. Am J Transplant 2011; 11: (Suppl. s2): S127.
43. Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 2004; 32: 1136-1140.
44. Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O'Brien A, Thuning-Roberson C, Edelman R, Tacket CO. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 2005; 49: 1808-1812.
45. Taylor CP, Tummala S, Molrine D, Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 2008; 26: 3404-3409.
46. Zhou B, Lin B, Li J, Qian W, Hou S, Zhang D, Kou G, Li B, Wang H, Chen Y, Guo Y. Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. MAbs 2012; 4: 110-119.
47. Line BR, Breyer RJ, McElvany KD, Earle DC, Khazaeli MB. Evaluation of human anti-mouse antibody response in normal volunteers following repeated injections of fanolesomab (NeutroSpec), a murine anti-CD15 IgM monoclonal antibody for imaging infection. Nucl Med Commun 2004; 25: 807-811.
48. Hodsman GP, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, Pouliquen I. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 2013; 75: 118-128.
49. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle T, Hoek FJ, van Deventer SJ, van der Poll T. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605.
50. Lazar H, Horn MP, Zuercher AW, Imboden MA, Durrer P, Seiberling M, Pokorny R, Hammer C, Lang AB. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 3442-3446.
51. Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Fujinaga S, Matsumoto Y, Masuho Y. Phase 1 study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 1991; 10: 278-285.
52. Riddle V, Leese P, Blanset D, Adamcio M, Meldorf M, Lowy I. Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Vaccine Immunol 2011; 18: 2136-2142.
53. White B, Leon F, White W, Robbie G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther 2009; 31: 728-740.
54. Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, Li H, Holland PC, Johnson S, Stein K, Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother 2010; 54: 2431-2436.
55. Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor EM, Losonsky GA, Motavizumab Study Group. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009; 28: 267-272.
56. Subramanian GM, Cronin PW, Poley G, Weinstein A, Stoughton SM, Zhong J, Ou Y, Zmuda JF, Osborn BL, Freimuth WW. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41: 12-20.
57. Beliard R, Waegemans T, Notelet D, Massad L, Dhainaut F, Romeuf C, Guemas E, Haazen W, Bourel D, Teillaud JL, Prost JF. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141: 109-119.
58. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361: 135-144.
59. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-1118.
60. Liles WC, Dale DC, Price TH, Gaviria JM, Turner T, Saoud J, Frumkin LR. Inhibition of in vivo neutrophil transmigration by a novel humanized anti-CD11/CD18 monoclonal antibody. Cytokines Cell Mol Ther 2000; 6: 121-126.
61. Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 1996; 174: 463-469.
62. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002; 71: 235-245.
63. Verhamme P, Pakola S, Glazer S, Stassen J, Cahillane G, Jensen TJ, Saint-Remy J, Sonesson E, Giessen P, Hoylaerts M, Jacquemin M. Thrombogram analysis of the long-acting anticoagulant effect of TB-402, a human anti-FVIII antibody, and of its interactions with rhFVIII, LMWH and warfarin in healthy volunteers. J Thromb Haemost 2009; 7: (Suppl. 2): abstract OC-TH-057.
64. Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010; 32: 1205-1220.
65. MacDougall Biomedical Communications. Theraclone Sciences press release. Available at http://www.theraclone-sciences.com/pdf/TCN-032%20Phase%201%20Data%20FINAL%20050912.pdf (last accessed 18 March 2013).
66. Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 959-962.
67. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006; 23: 95-103.
68. Graff J, Klinkhardt U, Westrup D, Kirchmaier CM, Breddin HK, Harder S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. Br J Clin Pharmacol 2003; 56: 321-326.
69. Harder S, Kirchmaier CM, Krzywanek HJ, Westrup D, Bae JW, Breddin HK. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation 1999; 100: 1175-1181.